p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances

CDKN2A is a tumor suppressor gene encoding the p16 protein, a key regulator of the cell cycle. CDKN2A homozygous deletion is a central prognostic factor for numerous tumors and can be detected by several techniques. This study aims to evaluate the extent to which immunohistochemical levels of p16 ex...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancers Ročník 15; číslo 5; s. 1512
Hlavní autori: Geyer, Lucas, Wolf, Thibaut, Chenard, Marie-Pierre, Cebula, Helene, Schott, Roland, Noel, Georges, Guerin, Eric, Pencreach, Erwan, Reita, Damien, Entz-Werlé, Natacha, Lhermitte, Benoît
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI AG 28.02.2023
MDPI
Predmet:
Antibodies
Biopsy
Brain cancer
Brain tumors
Cancer
Cell cycle
Central nervous system
Classification
Clonal deletion
Cloning
Cyclin-dependent kinases
Fluorescence in situ hybridization
Gene deletion
Gene expression
Gene mutations
Genetic aspects
Glioma
Gliomas
Immunohistochemistry
Kinases
MAP kinase
Medical prognosis
Methods
Nervous system
Oncology, Experimental
p16 Protein
Patients
Pediatrics
Phase transitions
Prognosis
Proteins
Tumor proteins
Tumor suppressor genes
Tumors
Variables
France
FISH
immunohistochemistry
p16
gliomas
prognosis
CDKN2A deletion
ISSN:2072-6694, 2072-6694
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:CDKN2A is a tumor suppressor gene encoding the p16 protein, a key regulator of the cell cycle. CDKN2A homozygous deletion is a central prognostic factor for numerous tumors and can be detected by several techniques. This study aims to evaluate the extent to which immunohistochemical levels of p16 expression may provide information about CDKN2A deletion. A retrospective study was conducted in 173 gliomas of all types, using p16 IHC and CDKN2A fluorescent in situ hybridization. Survival analyses were performed to assess the prognostic impact of p16 expression and CDKN2A deletion on patient outcomes. Three patterns of p16 expression were observed: absence of expression, focal expression, and overexpression. Absence of p16 expression was correlated with worse outcomes. p16 overexpression was associated with better prognoses in MAPK-induced tumors, but with worse survival in IDH-wt glioblastomas. CDKN2A homozygous deletion predicted worse outcomes in the overall patient population, particularly in IDH-mutant 1p/19q oligodendrogliomas (grade 3). Finally, we observed a significant correlation between p16 immunohistochemical loss of expression and CDKN2A homozygosity. IHC has strong sensitivity and high negative predictive value, suggesting that p16 IHC might be a pertinent test to detect cases most likely harboring CDKN2A homozygous deletion.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15051512